- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02377271
ENDOTHELION Studiegroep: Effect van Bosentan bij NAION-patiënten (ENDOTHELION)
Effect van Bosentan bij patiënten met niet-arteritische ischemische optische neuropathie
Acute ischemic optic neuropathy are the second leading cause of optic neuropathy after glaucoma in the population aged over 50 years. The visual prognosis of the condition is unfavorable in the great majority of cases, with significant effects on the visual field and vision. The severity of the unilateral condition is also associated with bilateralization in 15% at 5 years. There is no effective treatment for the acute phase of the disease or to reduce the rate of bilateralization. In this context, it is essential to develop new therapeutic strategies in the acute phase of the disease to reduce the anatomical optic nerve damage.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
The main objective of our study will be to compare the treatment with bosentan to placebo for 8 weeks for recovery anatomical criteria (RFNL in OCT, optic atrophy) and functional (visual acuity, visual field). The primary endpoint will be the improvement of the visual field, a major criterion of the affected visual function in this disease.
The evaluation of bosentan will mainly after 8 weeks of treatment in order to assess the effectiveness of drug treatment in the absence of continuous positive airway pressure (set up after three months if necessary, feasible confounding factor for the evaluation of results ), the period of three months is sufficient to assess the anatomical and functional recovery (disappearance of papilledema).
Studietype
Inschrijving (Geschat)
Fase
- Fase 3
Contacten en locaties
Studie Locaties
-
-
-
Angers, Frankrijk, 49100
- University Hospital of Angers
-
Bordeaux, Frankrijk, 33000
- University Hospital of Bordeaux
-
Grenoble, Frankrijk, 38043
- CHU de Grenoble
-
Grenoble, Frankrijk, 38043
- University Hospital of Grenoble Michallon
-
Paris, Frankrijk, 75019
- Ophtalmological fondation of Rothschild + Bichat Hospital
-
Saint-Etienne, Frankrijk, 42055
- University hospital of Saint-Etienne
-
-
Paris
-
Paris, Paris, Frankrijk
- Centre National d'Ophtalmologie XV-XX
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Non arteritic ischemic optic neuropathy (NAION) with onset < 21 days
- Age ≥ 50 years old
- Signed informed consent form
- Patients affiliated with a national health insurance scheme or beneficiaries of such a scheme
Exclusion Criteria:
- Pregnant women, women in labour or breast-feeding mother
- Patients with other acute or chronic intercurrent ocular pathology interfering with visual acuity or visual field (diabetes, drug-induced or other retinopathy, other optic neuropathy including uni- or contralateral glaucoma and/or intraocular pressure > 30 mmHg, advanced cataract, corneal opacities, amblyopia < 5/10, severe myopia > -6 diopters, retinal disease)
- Simultaneous bilateral NAAION, 1 month apart or less
- Signs that may raise suspicion of other inflammatory neuropathy: arterial NAAION (Horton's disease), pain on eye movement or any signs suggestive of optic neuritis, known diagnosis of multiple sclerosis, history of inflammatory optic neuropathy (homo- or ipsi-lateral). A temporal artery biopsy should be performed if there are symptoms suggestive of Horton's disease, or if there is pale and/or diffuse edema, or obliteration of the associated central retinal artery.
- Patients with systolic blood pressure below 100 mmHg
- Patient with orthostatic hypotension (20 mmHg drop in SBP and/or 10 mmHg drop in DBP when moving to a standing position)
- Neurological history of vascular or tumour-related changes to the visual field or other optic neuropathy
- Systemic inflammatory disease
- Known allergy to bosentan
- Patients with moderate to severe hepatic impairment (Child-Pugh class B or C), biliary cirrhosis (serum levels of liver aminotransferases, aspartate aminotransferases (ASAT) and/or alanine aminotransferases (ALAT), greater than three times the upper limit of normal, bilirubin greater than twice normal)
- Estimated glomerular filtration rate (GFR) < 30 ml/min/1.73 m2
- Patients treated with drugs whose efficacy may be reduced by activation of cytochrome P450, 2C9, 3A4 and 2C19 isoenzymes
- Patients treated with amiodarone
- Patient treated with systemic corticosteroids (background treatment or treatment initiated at the time of NAAION diagnosis)
- Person deprived of liberty by judicial or administrative decision, adult protected by law, hospitalized person
- Ongoing participation in another clinical research study or in the exclusion period of another clinical study
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verdrievoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Bosentan
Bosentan at a dose of 125 mg two times daily, will be administered orally, twice a day, during eight weeks |
treatment by bosentan or placebo is randomized , 125 mg twice a day |
|
Placebo-vergelijker: Placebo
placebo drug , twice a day, during eight weeks |
treatment by bosentan or placebo is randomized |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
mean deviation of automated visual field
Tijdsspanne: 3 month
|
Humphrey 30-2 SITA-standard |
3 month
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
visual acuity
Tijdsspanne: 6, 12 and 24 month
|
ETDRS scale |
6, 12 and 24 month
|
|
optic nerve fiber layer thickness
Tijdsspanne: 3, 6, 12 and 24 month
|
OCT measurement |
3, 6, 12 and 24 month
|
|
mean deviation of automated visual field for healthy eye and NAION eye
Tijdsspanne: 3, 6, 12 and 24 month
|
Humphrey 30-2 |
3, 6, 12 and 24 month
|
|
inflammatory marker and prepro-endothelin dosing
Tijdsspanne: 3 month
|
RANTES, MCP-1, TNF-α, INF-γ, IL-6, IL-10 and TGF-β |
3 month
|
|
mean deviation of automated visual field for controlateral eye
Tijdsspanne: 24 month
|
Humphrey 30-2 sita-standard |
24 month
|
|
VFQ-25 score
Tijdsspanne: 3 and 12 month
|
VFQ-25 quality of life |
3 and 12 month
|
|
rate of bilateral occurence of NAION
Tijdsspanne: at 24 month visit
|
rate of bilateralization |
at 24 month visit
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Christophe Pr CHIQUET, Prof, MD, PhD, University Hospital, Grenoble
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Geschat)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Ziekten van het zenuwstelsel
- Vaatziekten
- Hart-en vaatziekten
- Oogziekten
- Oogzenuwziekten
- Ziekten van de hersenzenuw
- Optische neuropathie, ischemische
- Zwavelverbindingen
- Organische chemicaliën
- Heterocyclische verbindingen, 1-ring
- Heterocyclische verbindingen
- Koolwaterstoffen
- Koolwaterstoffen, cyclisch
- Koolwaterstoffen, aromatisch
- Amides
- Pyrimidines
- Benzeenderivaten
- Benzenulfonamides
- Sulfonamides
- Sulfonen
- Bosentan
Andere studie-ID-nummers
- 2014-000848-14
- 2014 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .